Looking for an oncology reboot, Sanofi, Regeneron shoot for a fast and flashy FDA OK of a promising new PD-1
There’s another PD-1 drug headed toward the market. And this fast-moving — and often overlooked — program is due to arrive at the FDA for marketing review in just a matter of months.
In an outline of Sanofi’s R&D work for the Q2 call this week, research chief Elias Zerhouni was clearly excited by the “fast-to-market strategy in the PD-1 space” that has been set up with its big development partner Regeneron $REGN.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
